Document is current
Any future updates will be listed below
-
Authors
le Rütte, T. A.
Kerkhof, M.
Gerritsma, Y. H.
Driessen-Roelfszema, M. M. G.
van den Bemt, L.
Muris, J. W. M.
Riemersma, R. A.
Sandelowsky, H.
Stridh, B.
Kocks, J. W. H.
- License Information
-
More Information
Article History
Received: 10 May 2024
Accepted: 23 April 2025
First Online: 29 September 2025
Competing interests
: T.R., M.K., Y.G. and M.D. were employed by General Practitioners Research Institute (GPRI) at the time of the study. In the past four years, GPRI conducted investigator- and sponsor-initiated research funded by noncommercial organizations, academic institutes, and pharmaceutical companies (including AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Mundipharma, Novartis, and Teva). J.K. reports grants, personal fees and nonfinancial support from AstraZeneca; grants, personal fees and nonfinancial support from Boehringer Ingelheim; grants and personal fees from Chiesi; grants, personal fees and nonfinancial support from GSK; nonfinancial support from Mundi Pharma; grants and personal fees from Teva; personal fees from MSD; personal fees from COVIS Pharma; personal fees from ALK-Abello; and grants from Valneva outside the submitted work. J.K. holds 5% shares of Lothar Medtec GmbH and is owner of the General Practitioners Research Institute.
